News & Press
GeNeuro: financial information and business update for the second quarter 2021
Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update.
GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies
Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies.
https://geneuro.ch/data/news/GeNeuro-PR-MSJournal-publication-EN.pdf
GeNeuro: successful €6 million private placement
Geneva, Switzerland, July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (“MS”), today announced the successful completion of a €6.0 million capital increase with cancellation of the preferential subscription rights through an international private placement only to certain qualified and institutional investors of 1,730,458 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the “Offering”, respectively).
https://geneuro.ch/data/news/2021-07-13-GeNeuro-Closes-Financing-ENG.pdf
GeNeuro presents data supporting pathogenic role of an endogenous retroviral protein (HERV-W ENV) in post-COVID neuropsychiatric syndrome Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic…
Paris, France and Geneva, Switzerland, July 5, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), presented new data showing that the neuropsychiatric symptomatology seen in “post-COVID” patients may be due to activation of HERV-W ENV expression in these individuals by SARS-CoV-2, and to its persistence long after the acute COVID phase. These data, presented at the first “Neuro Sciences Psychiatry and Neurology Days” held in Paris, France, on July 1-2, provide a biologic rationale explaining why so many COVID-19 patients develop long-term neurological and psychiatric symptoms. This could open the door for a therapeutic intervention with temelimab targeting HERV-W ENV.
https://geneuro.ch/data/news/2021.07.05-PR-GeNeuro-FondaMental-07052021-VF-EN.pdf
GeNeuro and CIRI Renew Collaboration Agreement and Expand Focus to Post-COVID Syndromes
Geneva, Switzerland, June 24, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), and the CIRI (International Center for Infectiology Research), in Lyon, France, a world-class research institute against infectious diseases, announced today the signing of an extension to their existing Research Collaboration Agreement.
https://geneuro.ch/data/news/2021.06.24-GeNeuro-PR-CIRI-new-agreement-EN-vf-1-.pdf
.
GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting
Geneva, Switzerland, June 1, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others:
Availability of documents and information for the annual shareholders’ meeting of May 27, 2021
Geneva, Switzerland, May 6, 2021 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-lesOuates, Geneva, Switzerland.
https://geneuro.ch/data/news/GeNeuro-2021-AGM-Documents-Availability-EN.pdf
Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity
Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease severity.
https://geneuro.ch/data/news/GeNeuro-HERV-and-Covid-ENG-April-15-2021.pdf
GeNeuro : financial information for the first quarter 2021
Geneva, Switzerland, April 9, 2021 – 6.00pm CEST
Strong financial situation and visibility:
- Net cash position of €4.8 million
- Debt free
- Company’s operations funded until Q2-2022
GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 6, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a clinical-stage biopharmaceutical company leveraging the biology of human endogenous retroviruses (HERVs) to develop new treatments to stop the progression of neurodegenerative and autoimmune diseases, reported today its full-year results for the year ended December 31, 2020 and provided a corporate update
https://geneuro.ch/data/news/2021.04.06-GeNeuro-PR-FYR2020results-EN-vf.pdf
GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting
Geneva, Switzerland, March 2, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS patients should continue as planned without modification. This follows a pre-determined review of the first 8 patients treated with temelimab for 2 months at doses of 18, 36 and 54 mg/kg. The study, called ProTEct-MS, is being conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden).
https://geneuro.ch/data/news/GeNeuro-MS-Study-DSMB-Approval-ENG.pdf
GeNeuro completes patient recruitment in temelimab Phase 2 multiple sclerosis trial at the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.
https://geneuro.ch/data/news/PR-GeNeuro-MS-Study-Enrollment-Complete-EN-021821-VF.pdf